Endpoints News
Viatris' $1.65B bid for Pacira Read in browser
Endpoints News
Thank you for reading, Test Researcher!
basic
UPGRADE
M T W Thu F
8 October, 2026
PARTNER OF CHOICE FOR BIOLOGICS MANUFACTURING
Avid Bioservices is the partner of choice for biologics innovators seeking scientific expertise, operational excellence, and reliable execution from clinic to commercial.
sponsored by Avid Bioservices, Inc.
presented by iRegene
iRe­gene Ther­a­peu­tics’s Nou­vSight001 Cleared for Clin­i­cal Tri­als in the U.S. and Chi­na for Re­tini­tis Pig­men­tosa
top stories
1. New PDUFA deal allots money to rehire FDA reviewers, trade groups say
2. Viatris to make $1.65B Pacira acquisition, adding to momentum in pain
3. Argenx's study flop in Sjögren's overshadows a win in celiac disease
4. Zealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacle
5. Long ignored by drugmakers, preeclampsia is now a focus for WHO and biopharma
more stories
• 
Lydia Ramsey Pflanzer
.

Yes, it's October, and yes that means it's already time to start talking about Endpoints' annual JP Morgan Healthcare Conference event! Join us Jan. 11 and 12 for some great conversations about what's ahead for biopharma in 2027. Find virtual and in-person ticket options here.

.
Lydia Ramsey Pflanzer
Deputy Editor, Endpoints News
1
by Max Bayer

Top phar­ma­ceu­ti­cal trade groups say the FDA will have a ded­i­cat­ed pool of mon­ey to re­plen­ish its sta­ble of re­view­ers as part of the new...

Read the full story
2
by Kyle LaHucik

Vi­a­tris, a gener­ics and brand­ed med­i­cines mak­er, is buy­ing in­to non-opi­oid pain drugs with a cash ac­qui­si­tion of com­mer­cial-stage Paci­ra Bio­Sciences.

The Thurs­day morn­ing deal, val­ued at...

Read the full story
AI Day 2026 - October 14
Workforces restructured, AI-designed drugs in the clinic, record money chasing unknown potential, the transformation is already underway. Where does biopharma stand now? Register free for the virtual program and get the scoop.
3
by Ayisha Sharma

Ar­genx on Thurs­day re­port­ed one suc­cess and one set­back in its au­toim­mune dis­ease pipeline, send­ing its shares tum­bling.

The Bel­gian-Dutch phar­ma saidit is shut­ter­ing...

Read the full story
4
by Max Gelman

Zealand Phar­ma and Roche rolled out some mid-stage da­ta for their amylin drug in obe­si­ty and di­a­betes, hop­ing to com­pete with Eli Lil­ly.

In a...

Read the full story
5
by Kyle LaHucik

A preg­nan­cy-re­lat­ed hy­per­ten­sion dis­or­der that im­pacts mil­lions of moth­ers and new­borns each year is get­ting more at­ten­tion from the top lev­els of pub­lic health or­ga­ni­za­tions...

Read the full story
Endpoints News
2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com
web twitter linkedin